Charles River Laboratories Intl. Inc vs Exxon Mobil Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Exxon Mobil Corporation trades at $168.94 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 48.7× Charles River Laboratories Intl. Inc's market cap, and Exxon Mobil Corporation pays a 2.45% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Exxon Mobil Corporation for 99 Days on average.
| CRL | XOM | |
|---|---|---|
Market Cap | $14.23B | $692.86B |
Volume | 1,176,885 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $310.77 | $171.52 |
52-Week Low | $149.93 | $110.64 |
Typical Hold Time | 33 Days | 99 Days |
Enterprise Value | $17.06B | $724.64B |
Dividend Yield | — | 2.45% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Exxon Mobil (XOM) trades at $168.56, up 2.74% today, with a bullish technical signal from moving averages and a consensus analyst price target of $166.67. Recent earnings show mixed results, with a Q2 2026 miss but beats in prior quarters. Revenue has declined from $398.7B in 2022 to $323.9B in 2025, though 2026 projects a rebound to $361.1B. News highlights potential investment in Venezuela's oil fields and expansion in Guyana and the Permian Basin.
XOM presents a stable investment with a 12.55% ROE and dividend yield, but faces risks from volatile oil prices and geopolitical ventures. Analyst sentiment is mixed with 36.36% buy ratings, indicating cautious optimism amid execution risks and macroeconomic pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →